User:Amol Deshpande

From InnovationCell

Jump to:navigation, search


Amol Deshpande

Advisor
Amol Deshpande.png
Advisory board


Amol Deshpande is a practicing physician in Toronto, dividing his efforts between clinical medicine in chronic non-cancer pain and innovative ventures to change healthcare. 
Amol practiced clinical medicine for several years, in a variety of settings, before obtaining his MBA. Since then, he has participated in numerous projects involving eHealth, evidence-based decision-making and telehealth. He is the primary author of systematic reviews in real-time telehealth, asynchronous telehealth and telestroke as well as one of the first articles on Web 2.0 in healthcare published in a peer-review medical journal. 
His business interests have led him to the position of Chief Medical Officer for Wellocities, an online social computing site designed for diabetics and a consultant to a number of web based start-ups in the health space. He is co-founder of HelixHealth, a clinic focused on employee well-being through early genetic detection and disease management. 
Amol obtained his medical degree from the University of Toronto and his MBA from the Rotman School of Management.


Description
A Roadmap to Innovation: Accelerating Ideas through the Innovation Cell In a relatively short period of time, the Cell has amassed a brand and network that has global reach in the health 2.0 industry (global ecosystem). This unique position has allowed the Cell to interact with many individuals, patients, health providers and organizations that continually generate innovative ideas for the health system. While the Cell aggregates and disseminates these ideas, innovation -- beyond idea generation -- encompasses the ability to nurture those specific concepts that are most likely to succeed in the marketplace.


In order to accomplish this task, a structured analytical framework is required in order to move idea generation to health innovation, fulfilling the Cell's original mandate of "game changing" business model innovation and leveraging its growing brand into a global health system player. This framework would ensure a thorough and thoughtful analysis that takes into account many factors including the contribution to the health value chain, impact on existing business models and incumbant players, and the ultimate likelihood of success, providing direction for the most effective utilization of internal and external resources, prioritization, etc. In the absence of such a process, many key elements of a potentially successful innovation may be neglected resulting in acceptance of a poorly developed idea. Worse, without such a schema, it could result in rejection of a game-changing theory that has the potential to deliver significant value to the heath system and its people.

The development of a schema also has added benefits beyond the efficiencies created in evaluating internal and external ideas in the health 2.0 industry; including the development and fostering of collaborative partners and inter-dependencies, growth of the Innovation Cell's ecosystem, core brand, global media footprint and the creation of Canada's premier resource for health 2.0 players.
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants This project was undertaken to develop a rapid method for obtaining a widespread sample of patient views on the efficacy and side-effects of antidepressants.

A Web-based method is described for rapidly and objectively obtaining patient views on the effects and side-effects of treatment with antidepressants. The method entails a systematized search of many URLs (Uniform Resource Locators, or Web page addresses), using keywords and phrases to extract the named drug and symptom that are reliably relevant to the medication being taken by the individual reporting the experience online. Unwanted medical conditions (e.g., cancer) are excluded.

Three successive searches of thousands of Web pages revealed a cumulative total of 835 "mentions" of patient experience on duloxetine, 756 for venlafaxine, 637 for citalopram, 636 for sertraline, 559 for paroxetine, 457 for fluoxetine, 318 for desvenlafaxine, 289 for fluvoxamine, and 210 for mirtazapine, in association with various symptoms. A comparison of the associated symptoms for each of the antidepressants found that the prevalence of the combined factor of fatigue, drowsiness, tiredness or lethargy ranged from 6.4+/-0.8% down to 2.9+/-0.15% of the mentions, where the S.E. was derived from three repeats of the Web-based analysis. The prevalence of dizziness or vertigo ranged from 7.6+/-0.8% down to 1.9+/-0.3% of the mentions.

Given the increasing number of patient narratives about drug experiences on open-access Web forums, this rapid novel method will have increasing utility in post-marketing surveillance and in comparing the effects of psychiatric medications.

PMID: 20705344 [PubMed - as supplied by publisher]


Navigation
Toolbox